Kevin A Hommel1, Robert N Baldassano. 1. Cincinnati Children's Hospital Medical Center, Center for the Promotion of Treatment Adherence and Self-Management, Division of Behavioral Medicine and Clinical Psychology, Cincinnati, OH 45229-3039, USA. kevin.hommel@cchmc.org
Abstract
OBJECTIVE: To examine perceived barriers to medication adherence in inflammatory bowel disease (IBD) treatment and their relationship with adherence using a combined forced choice and semi-structured interview assessment approach. METHODS: Sixteen adolescents with IBD and their parents participated in an open-ended interview regarding adherence barriers and completed quantitative measures of adherence, barriers to treatment, and disease severity. RESULTS: The most commonly identified barriers to adherence were forgetting, interference with other activities, difficulty swallowing pills, and not being at home. Number of reported barriers was positively correlated with objective nonadherence for 6-MP/azathioprine. Nonadherence frequency was 42% for 6-MP/azathoprine and 50% for 5-ASA medications. CONCLUSIONS: Using a combined assessment approach, patients and parents reported several barriers to treatment adherence that are appropriate for clinical intervention. This is critical given the significant medication nonadherence observed in this sample and the relationship between total number of barriers and disease management problems.
OBJECTIVE: To examine perceived barriers to medication adherence in inflammatory bowel disease (IBD) treatment and their relationship with adherence using a combined forced choice and semi-structured interview assessment approach. METHODS: Sixteen adolescents with IBD and their parents participated in an open-ended interview regarding adherence barriers and completed quantitative measures of adherence, barriers to treatment, and disease severity. RESULTS: The most commonly identified barriers to adherence were forgetting, interference with other activities, difficulty swallowing pills, and not being at home. Number of reported barriers was positively correlated with objective nonadherence for 6-MP/azathioprine. Nonadherence frequency was 42% for 6-MP/azathoprine and 50% for 5-ASA medications. CONCLUSIONS: Using a combined assessment approach, patients and parents reported several barriers to treatment adherence that are appropriate for clinical intervention. This is critical given the significant medication nonadherence observed in this sample and the relationship between total number of barriers and disease management problems.
Authors: Maria M Oliva-Hemker; Vivian Abadom; Carmen Cuffari; Richard E Thompson Journal: J Pediatr Gastroenterol Nutr Date: 2007-02 Impact factor: 2.839
Authors: J S Hyams; G D Ferry; F S Mandel; J D Gryboski; P M Kibort; B S Kirschner; A M Griffiths; A J Katz; R J Grand; J T Boyle Journal: J Pediatr Gastroenterol Nutr Date: 1991-05 Impact factor: 2.839
Authors: S Lichtiger; D H Present; A Kornbluth; I Gelernt; J Bauer; G Galler; F Michelassi; S Hanauer Journal: N Engl J Med Date: 1994-06-30 Impact factor: 91.245
Authors: Kevin A Hommel; Julia Carmody; Andrew D Hershey; Christina Holbein; Marielle Kabbouche-Samaha; James Peugh; Scott Powers Journal: Headache Date: 2020-04-22 Impact factor: 5.887
Authors: Kevin A Hommel; Wendy N Gray; Elizabeth Hente; Katherine Loreaux; Richard F Ittenbach; Michele Maddux; Robert Baldassano; Francisco Sylvester; Wallace Crandall; Charles Doarn; Melvin B Heyman; David Keljo; Lee A Denson Journal: Contemp Clin Trials Date: 2015-05-21 Impact factor: 2.226
Authors: Yelena P Wu; Bridget G Parsons; Lisa G Aspinwall; Jennifer L Hay; Kenneth M Boucher; Heloisa Caputo; Ryan Mooney; Douglas Grossman; Sancy A Leachman Journal: Pediatr Dermatol Date: 2019-03-20 Impact factor: 1.588
Authors: Jamie L Ryan; Michael W Mellon; Katherine W F Junger; Elizabeth A Hente; Lee A Denson; Shehzad A Saeed; Kevin A Hommel Journal: Inflamm Bowel Dis Date: 2013-11 Impact factor: 5.325